EP Patent

EP1591114A1 — Use of metformin and orlistat for the treatment or prevention of obesity

Assigned to Fournier Laboratories Ireland Ltd · Expires 2005-11-02 · 21y expired

What this patent protects

The present invention relates to the use of metformin and orlistat to treat patients suffering from obesity.

USPTO Abstract

The present invention relates to the use of metformin and orlistat to treat patients suffering from obesity.

Drugs covered by this patent

Vascepa (ICOSAPENT ETHYL) · Amarin Pharms

Patent Metadata

Patent number: EP1591114A1
Jurisdiction: EP
Classification: —
Expires: 2005-11-02
Drug substance claim: No
Drug product claim: No
Assignee: Fournier Laboratories Ireland Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.